AzTrials
AzTrials

GonarthrosisTAGSNCT06314191

Adipose Tissue and Symptomatic Gonarthrosis

A study testing blood sampling and knee radiography in people with Gonarthrosis and Obesity, run by Centre Hospitalier Universitaire de Nice at 1 site in France.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

1. Prevalence of osteoarthritis in France Osteoarthritis (OA) is a very common disease, affecting almost 15% of the population. It is responsible for a significant socio-economic cost in connection with the chronic and disabling pain it causes . Gonarthrosis is the most frequently encountered arthritic localization . Read more about this study

Who is it for?
Ages 30 to 55 yearsHealthy volunteers can take part
Conditions the study is for
Gonarthrosis, Obesity
What is being tested?
blood sampling and knee radiography
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
1 siteFrance
Study dates
15 Jun 2024to 15 Nov 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 30 to 55 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Patients aged between 30 and 55.
  • Patient with BMI > 40 or Patient with BMI between 35-40 and presence of hypertension and/or diabetes and/or obstructive sleep apnea syndrome.
  • Patients scheduled for bypass or SLEEVE bariatric surgery.
  • Patients with symptomatic gonarthrosis or patients with no signs of osteoarthritis.
  • Patients who have given written consent following written and oral information.
  • Patient affiliated to a social security scheme.

Who cannot join

  • Patient having undergone knee ligamentoplasty.
  • Patient with knee infiltration less than three months old.
  • In the group of patients with no osteoarthritis, no known osteoarthritis or signs of osteoarthritis in a joint other than the knee.
  • Patients treated with lipid-lowering or cholesterol-lowering drugs
  • Postmenopausal patients
  • Patient with weight change of more than 5% in the last 3 months
Show all 12Show fewer
  • Patients with known systemic inflammatory or autoimmune diseases
  • Patients on special diets in the last 3 months (gluten-free, high-protein, low-carbohydrate diets)
  • Patient with knee pain of secondary origin: tumor, inflammation, infection, fracture
  • Patient with a contraindication to bariatric surgery
  • Patient protected by law under guardianship or curatorship, or unable to participate in a clinical study under article L. 1121-16 of the French Public Health Code.
  • Patient with insufficient command of the French language (assessed during interview).

Trial locations and contacts

1 site in 1 country.

Christian ROUX contact

0492039220

roux.c2@chu-nice.fr

France1 site
  • Nice University Hospital

    Nice, 06000

    Christian Roux, 0492039220, roux.c2@chu-nice.fr

    Isa Costantini, 0492039220, constantini.i@chu-nice.fr

Other trials in France

About this study

Official title: Comparative Study to Identify Biomarkers of Visceral Adipose Tissue Responsible for Symptomatic Gonarthrosis in Obese Patients

  1. Prevalence of osteoarthritis in France Osteoarthritis (OA) is a very common disease, affecting almost 15% of the population. It is responsible for a significant socio-economic cost in connection with the chronic and disabling pain it causes . Gonarthrosis is the most frequently encountered arthritic localization . In a large 2010 meta-analysis, the main risk factors for developing knee OA were shown to be obesity, previous knee trauma, hand OA, female gender and advanced age. Smoking appeared to have a moderate protective effect . The risk of developing gonarthrosis in obese patients is 2.6 times higher than in the general population. Hypercholesterolemia itself is a risk factor for osteoarthritis, as are increased plasma levels of specific fatty acids and lipoproteins Inflammatory mechanism in osteoarthritis. Studies have shown that plasma levels of C-reactive protein, can be used to estimate individual susceptibility to developing osteoarthritis over a lifetime . In osteoarthritis patients, plasma concentrations of TNF-α, IL-6 and IL-1 are abnormally high, which appears to contribute to cartilage loss in these subjects .
  2. Inflammatory mechanism in obesity. Obesity induces systemic and local joint mechanical stresses that increase the risk of developing gonarthrosis in obese or overweight individuals . Beyond the simple mechanical aspect, a body of evidence supports the assertion that obesity is responsible for a systemic inflammatory state, deleterious to joints. 1) Obesity is associated with radiographic and symptomatic osteoarthritis in non-weight-bearing joints, such as the hand In overweight and obese adults, plasma levels of tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) are significantly increased .

3)Weight loss in obese subjects with osteoarthritis alleviates joint symptoms through reduced mechanical stress but also through reduced production and response of inflammatory products .

Read more
  1. Common inflammatory mechanisms between adipose tissue and obesity. The relationship between adipose tissue and inflammation is complex given the different types of adipose tissue and the action of cells derived from it. Adipose tissue is an active endocrine organ composed of mature and developing adipocytes, as well as fibroblasts, endothelial cells and a wide range of immune cells, namely adipose tissue macrophages, neutrophils, eosinophils, mast cells, T cells and B cells. Adipose tissue is recognized as an endocrine organ that secretes a large number of inflammatory mediators, including cytokines (IL-1, IL-6, IL-8, TNF-α) and adipokines (leptin, adiponectin, resistin, visfatin). Communication between adipocytes and immune cells maintains tissue homeostasis. Obesity, however, can upset this balance.

Lipid metabolism and joint disorders have been shown to be linked . A high-fat diet may contribute to the development of osteoarthritis .

White and brown adipose tissue appear to play a complementary role in the development of osteoarthritis. Increased white adipose tissue in obesity is thought to create a systemic environment of increased inflammation through the release of pro-inflammatory cytokines and adipokines such as leptin and visfatin, all of which have been associated with osteoarthritis . Locally, white adipocytes in infra patellar adipose tissue are architecturally different in patients without gonarthrosis compared with those with knee osteoarthritis. This difference suggests that adipocyte gene expression is directly influenced by inflammation . In obese individuals, there is elevated IL-6 production in brown adipose tissue . Furthermore, it would appear that brown adipose tissue, unlike white, down-regulates the inflammatory profile of macrophages .

Being tested
blood sampling, knee radiography
Medical subject headings
Osteoarthritis, Knee, Obesity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • blood samplingOther

    blood sampling with analyses

  • knee radiographyOther

    radiography of both knees in Schuss

Study groups in NCT06314191
Study groupRoleWhat they receive
arthrose groupExperimentalNot described
Receives: Other: blood sampling; Other: knee radiography
controle groupActive comparatorNot described
Receives: Other: blood sampling; Other: knee radiography

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. lipolytic activity

    glycerol dosage in mg/dL

    Measured: baseline and perioperatively

  2. lipolysis measurement

    HSL dosage (%)

    Measured: baseline and perioperatively

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Mar 2024
  2. Study start15 Jun 2024 (estimated)
  3. Primary completion15 Jun 2025 (estimated)
  4. Study completion15 Nov 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
20 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06314191
Sponsor's protocol ID
23-AOIP-02
Acronym
TAGS
Status last verified
May 2024
First submitted
1 Mar 2024
Last updated
17 May 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing blood sampling and knee radiography in people with Gonarthrosis and Obesity, run by Centre Hospitalier Universitaire de Nice at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 17 May 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Christian ROUX (0492039220, roux.c2@chu-nice.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

lipolytic activity (time frame: baseline and perioperatively). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 May 2024.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in